15 assets in T-Cell Childhood Lymphoblastic Lymphoma

Therapeutic assets addressing T-Cell Childhood Lymphoblastic Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Bortezomib T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Cyclophosphamide T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Cytarabine T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Daunomycin T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Dexasone T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Etoposide T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Hydrocortisone T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Isocyclophosphamide T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Mercaptopurine Anhydrous T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Pegaspargase T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Thioguanine Anhydrous T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
(+)-Vincristine T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Vincristine Sulfate T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (60)
Methotrexate T-Cell Childhood Lymphoblastic Lymphoma	National Cancer Institute (NCI)	P3	B (58)